The biopharma industry continues to face challenges this year, with projected returns on investment in R&D at the lowest levels since our analysis began in 2010. However, there are opportunities to reverse this trend, which will require new ways of working and a complete digital transformation to unlock R&D productivity and deliver the next generation of scientific breakthroughs.


The University of Maryland, Baltimore has granted Educational & Scientific, LLC an exclusive license with the potential to treat prostate cancer, UM Ventures announced Monday. The agreement allows Educational & Scientific to develop Galeterone, a molecule that could inhibit prostate cancer growth in patients with castration-resistant prostate cancer. The molecule has had successful Phase 1 and Phase ...


The research institute founded and headed by J. Craig Venter, Ph.D., yesterday won the dismissal of a federal lawsuit filed against it by the company he co-founded four years ago to develop and apply large-scale computing and machine learning toward making discoveries intended to revolutionize the practice of medicine. Judge William Q. Hayes of U.S. District Court for the Southern District of California sided with the J. Craig Venter Institute (JCVI) by dismissing the lawsuit brought against it by Human Longevity Inc. (HLI), the company Venter co-founded in 2014.


General Electric has filed paperwork for an IPO of its health-care unit, GE Healthcare, according to people familiar with the matter.

GE is working with JPMorgan Chase on an initial public offering that would likely come mid-2019, someone familiar with the plans told CNBC. Goldman Sachs, Bank of America, Citigroup and Morgan Stanley are also working with GE, according to Bloomberg News. The new public company would rank among the largest in the world.


It wouldn’t be a stretch to call 2018 the year RNA-based treatments, such as those applying RNA interference (RNAi) or small interfering RNA (siRNA), finally reached the proverbial tipping point predicted ever since Andrew Z. Fire and Craig C. Mello won the 2006 Nobel Prize in Physiology or Medicine for discovering RNAi.


Emergent BioSolutions Inc. (NYSE:EBS) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for its anthrax vaccine, BioThrax® (Anthrax Vaccine Adsorbed). BioThrax is indicated for active immunization for the prevention of disease caused by Bacillus anthracis, in individuals 18 through 65 years of age, whose occupation or other activities place them at risk of exposure, regardless of the route of exposure. BioThrax is administered in a three-dose primary schedule (0, 1 and 6 months) with boosters at three-year intervals recommended thereafter. BioThrax was approved under the Extraordinary Use New Drug Regulations, which provide a regulatory pathway for products for which collecting clinical information for its intended use in humans is logistically or ethically not possible.


Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today has announced that the Eversense® Continuous Glucose Monitoring (CGM) System has been awarded one of Popular Science’s 2018 “Best of What’s New” Awards in the Health category.